

**Annual Meeting of the Roll Back Malaria (RBM) - Malaria in Pregnancy (MiP)  
Working Group Meeting  
*Commitment to strengthening, accelerating and supporting MiP programming*  
13-14 May, 2013/Geneva/ WHO HQ/ Room M405  
AGENDA**

Despite clear gains in malaria control, MiP interventions still remain suboptimal with IPTp-SP uptake and ITN use far below global targets. Poor outcomes combined with the known devastating consequences of MiP on maternal and newborn health have ignited a renewed interest to improve malaria in pregnancy programs, address missed opportunities and increase coverage of these life-saving interventions for all pregnant women. The RBM MiP WG is committed to optimizing the delivery of key MiP intervention through the dissemination of successful technical guidance and programmatic approaches, fostering partnership between national reproductive health and malaria control programs and engaging key partners at both global and country level to help accelerate implementation and increase nation-wide coverage.

**Key Meeting Objectives:**

- 1. Review and discuss new WHO IPTp policy dissemination and adoption.**
- 2. Review and discuss country progress.**
- 3. Review and discuss new technical evidence and key programming updates.**
- 4. Review and update MiP working group work plan.**

## DAY ONE: May 13, 2013

### Day 1 Objectives:

1. Review and discuss new WHO IPTp policy dissemination and adoption.
2. Review and discuss country progress

08:15 - 08:30	Registration
08:30 - 09:00	Welcome and Introduction (Koki Agarwal and Viviana Mangiaterra) Review of agenda and meeting objectives and expected outcomes (Viviana Mangiaterra)  Welcome from Dr. Nafo/ RBM  Opening remarks from Dr. Mason/ WHO, Director of Maternal, Newborn, Child and Adolescent Health
09.00 - 09.45	An Overview of MIP Programming in the Last Year & Future Directions- Koki Agarwal  Discussion

### A Review of MIP Programming in the Last Year

09:45 - 10:45	MIP beyond 2015 and MDGs WHO- Viviana Mangiaterra  PMI Update- Susan Youll  Gates Update- David Brandling Bennett  Discussion
---------------	---

### 10:45 – 11:15 **TEA/COFFEE BREAK**

### MIP Policy Dissemination and Adoption

11:15 – 12:00	Where are we now? Progress in Dissemination of IPTp Policy and Adoption- TBD  Review of Updated WHO ANC guidelines and materials- TBD  Discussion
---------------	---

12:00- 13:00 Further Technical Review: Evidence Review Group- IPTp and Malaria Policy  
Advocacy Committee- Andrea Bosman

Harmonized or Not? A Review of MIP Policies in Five Countries- Elaine Roman

Discussion

13:00 - 14:00 **LUNCH**

### **Country and Regional Program Updates**

14:00- 14:45 Addressing Challenges and Accelerating Progress in MIP Programs

- PATH- Country Action Plans- Michel Pacqué

Discussion

14:45- 15:15 **TEA/COFFEE BREAK**

15:15- 16:30 Regional Network Updates- Regional Support to Accelerate MIP Programming

- SARN
- EARN
- CARN
- WARN

- *Discussion*

16:30- 16:45 Wrap Up of Day 1/ Announcements

## **Day TWO: MAY 14, 2013**

### **Day 2 Objective:**

- 1. Review and discuss new technical evidence and key programming updates.**
- 2. Review and update MIP working group work plan.**

09.00 - 09.15 Overview of Day 1- Koki Agarwal

### **Technical Evidence & Programmatic Considerations**

#### **MIP Research**

09:15- 10:30 IPTp Program Effectiveness Protocol: An Introduction- Jayne Webster

Discussion

10:30- 11:15 10:30- 11:15 Preliminary results from the multi-country consortium on the  
burden of P.vivax infection in pregnancy- Azucena Bardají

Discussion

11:15 –11:45

**TEA/COFFEE BREAK**

11: 45- 12:15

Cost-Effectiveness of Intermittent Preventive Treatment of Malaria in Pregnancy in Southern Mozambique- Clara Menendez

**Monitoring and Evaluation**

12:15 – 13:00

Monitoring MIP Programs

- Indicators for MIP programming: MERG Update: Richard Cibulskis

Discussion

13:00 - 14:00

**LUNCH**

**Work Planning**

14:00- 14:45

Where are we? An Overview of Priority Activities- Viviana Mangiaterra

14:45 – 15:15

**TEA/COFFEE BREAK**

15:15 – 16.45

- Next Steps- Koki Agarwal

Discussion

16:45—17:00

Closing remarks by Dr. Temmerman/WHO, Director of Reproductive Health and Research Department